Cipla Signs Exclusive Licensing Agreement with Formosa for Ophthalmic Drug

Cipla has entered into an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals to commercialise clobetasol propionate ophthalmic suspension (0.05%), known as APP13007. The agreement gives Cipla exclusive rights to market the drug in India, South Africa, Nepal, Sri Lanka, Bangladesh, Malaysia, Myanmar, Kenya, Nigeria, Argentina, and Colombia.

Following the announcement, Cipla Ltd shares were trading at ₹1,501.00, down by ₹7.65 (0.51%) as of 12:44 PM on March 19. Over the past six months, the stock has declined 8.35%, while it has gained 4.55% over the past year.

Drug Approval and Usage

APP13007 is a USFDA-approved, patent-protected ophthalmic drug developed for post-operative inflammation and pain management following ocular surgery. The formulation offers a twice-daily dosing regimen for 14 days without tapering, simplifying its usage compared to conventional corticosteroids.

Cipla’s Expansion in Ophthalmology

This is Cipla’s first multi-regional licensing agreement in ophthalmology. According to their regulatory filing, Achin Gupta, Global Chief Operating Officer at Cipla, stated that the agreement allows Cipla to expand access to the therapy across multiple countries. The company plans to utilise its commercial network to support the distribution of the drug.

Formosa Pharmaceuticals’ Role

Erick Co, President and CEO of Formosa Pharmaceuticals, said the company looks forward to working with Cipla to provide the treatment in new markets. Formosa Pharmaceuticals specialises in ophthalmic drug development and has been expanding its partnerships globally.

Conclusion

Cipla operates across multiple therapeutic areas and has been expanding its speciality drug portfolio. The ophthalmology market is to grow due to increasing eye surgeries and the demand for post-operative care solutions, as per the reports. This agreement adds to Cipla’s existing product line in the segment.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.